Clinical Trial Update: Safety and Efficacy Study of Ibuprofen l-Lysine Solution in Premature Infants for Treatment of PDA [Phase 3]

View source ↗

Summary

Phase 3 safety and efficacy study of ibuprofen l-Lysine solution for treating patent ductus arteriosus in premature infants has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Patent Ductus Arteriosus

Drugs mentioned

• Ibuprofen l-Lysine Solution (ibuprofen lysinate)

Snippet

Sponsor: Farmacon | Conditions: Patent Ductus Arteriosus | Phase 3 | Status: COMPLETED